{"id":752929,"date":"2025-07-22T06:24:01","date_gmt":"2025-07-22T06:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=752929"},"modified":"2025-07-22T06:24:01","modified_gmt":"2025-07-22T06:24:01","slug":"5ht2-agonist-clinical-trials-2025-ema-pdma-fda-approvals-medication-therapies-treatment-market-mechanism-of-action-route-of-administration-and-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/5ht2-agonist-clinical-trials-2025-ema-pdma-fda-approvals-medication-therapies-treatment-market-mechanism-of-action-route-of-administration-and-companies-by-delveinsight_752929.html","title":{"rendered":"5-HT2 Agonist Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/07\/1753012634.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"5-HT2 Agonist Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/07\/1753012634.jpg\" alt=\"5-HT2 Agonist Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>5-HT2 Agonist Clinical Trials<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">5-HT2 agonist companies such as Cybin, Reunion Neuroscience, BetterLife Pharma, Gilgamesh Pharmaceuticals, Harmony Biosciences, Mindmed, ATAI LIFE SCIENCES N.V, Reviva Pharmaceuticals, Beckley Psytech, MindBio Therapeutics and others.<\/div>\n<p style=\"text-align: justify;\">(Albany, USA) DelveInsight&rsquo;s <strong>&#8216;5-HT2 Agonist Pipeline Insight 2025&#8217;<\/strong> report provides comprehensive global coverage of pipeline 5-HT2 agonists in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the 5-HT2 agonist pipeline domain.<\/p>\n<p style=\"text-align: justify;\">Advancements in precision medicine drive the 5-HT2 agonist market by enabling selective targeting of specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety. Personalized approaches, like pharmacogenomics, identify patients most likely to benefit, enhancing treatment efficacy and adoption while accelerating drug development with cutting-edge technologies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Download sample report to know more about 5-HT2 Agonist Clinical Trial @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/5-ht2-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">5-HT2 Agonist Pipeline Insight<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the 5-HT2 Agonist Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s 5-HT2 agonist pipeline report depicts a robust space with<strong> 20+ <\/strong>active players working to develop <strong>22+ <\/strong>pipeline 5-HT2 agonists.<\/li>\n<li>Key 5-HT2 agonist companies such as <strong>Cybin, Reunion Neuroscience, BetterLife Pharma, Gilgamesh Pharmaceuticals, Harmony Biosciences, Mindmed, ATAI LIFE SCIENCES N.V, Reviva Pharmaceuticals, Beckley Psytech, MindBio Therapeutics <\/strong>and others are evaluating new 5-HT2 agonist drugs to improve the treatment landscape.<\/li>\n<li>Promising pipeline 5-HT2 agonists such as <strong>CYB003, RE104, BETR-001, GM2505, EPX-100, MM120, EMP 01, Brilaroxazine, Psilocybin infusion, MB-22001, <\/strong>and others are under different phases of 5-HT2 agonist clinical trials.<\/li>\n<li>In December 2024, Mind Medicine announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), had been granted an Innovation Passport for the potential treatment of GAD under ILAP by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).<\/li>\n<li>In October 2024, Lundbeck A\/S and Longboard Pharmaceuticals, Inc. announced an agreement for Lundbeck to acquire Longboard. Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment of USD 60.00 per share in cash.<\/li>\n<li>In October 2024, Bright Minds Biosciences Inc. a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, announced positive data from the preclinical testing of BMB-201 completed with National Institute of Health pain screening (PSPP) program.<\/li>\n<li>In March 2024, Mind Medicine announced that FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD). the company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Request a sample and discover the recent advances in 5-HT2 agonist drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/5-ht2-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">5-HT2 Agonist Pipeline Report<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The 5-HT2 agonist pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage 5-HT2 agonist drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the 5-HT2 agonist clinical trial landscape.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>5-HT2 Agonist Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">5-HT2 (5-hydroxytryptamine 2) agonists are a class of drugs that selectively activate 5-HT2 receptors, a subgroup of serotonin receptors located in the central nervous system. Serotonin also referred to as 5-hydroxytryptamine (5-HT), is a neurotransmitter that plays a critical role in regulating mood, cognition, and sensory processing. The 5-HT2 receptor family includes three main subtypes: 5-HT2A, 5-HT2B, and 5-HT2C.<\/p>\n<p style=\"text-align: justify;\">By binding to and stimulating these receptors, 5-HT2 agonists initiate a series of intracellular signaling cascades. These receptors, which are G protein-coupled receptors (GPCRs), influence key signaling pathways such as phospholipase C (PLC), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK). As integral membrane proteins with seven transmembrane domains, 5-HT2 receptors mediate serotonin&#8217;s effects by facilitating ligand binding, G protein coupling, and activation of downstream signaling, resulting in a variety of physiological and pharmacological outcomes. Understanding these mechanisms is crucial for developing therapeutic drugs targeting 5-HT2 receptors and for exploring their roles in health and disease.<\/p>\n<p style=\"text-align: justify;\">Therapeutic targeting of 5-HT2 receptors has shown promise in several medical fields due to their significant role in regulating physiological processes. In psychiatry, 5-HT2A agonists have demonstrated potential as treatments for depression and anxiety, with compounds like psilocybin (from psychedelic mushrooms) and lysergic acid diethylamide (LSD) showing efficacy in controlled clinical settings. Similarly, 5-HT2C agonists are being investigated for their ability to manage obesity and metabolic disorders by modulating appetite and energy balance. In neurology, 5-HT2B and 5-HT2C agonists are being studied for their vasoconstrictive effects in migraine management, while 5-HT2B agonists are also under exploration for their cardioprotective benefits in conditions such as heart failure.<\/p>\n<p style=\"text-align: justify;\">Despite their potential, the clinical application of 5-HT2 agonists requires careful consideration of their psychotropic effects and possible side effects. This highlights the need for rigorous research and controlled usage to optimize their therapeutic advantages.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Find out more about 5-HT2 agonist drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/5-ht2-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">5-HT2 Agonist Pipeline Analysis<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>A snapshot of the Pipeline 5-HT2 Agonist Drugs mentioned in the report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>CYB003: Cybin (Major depressive disorder)<\/li>\n<li>MM120 : MindMed\/The University Hospital of Basel (Anxiety disorders)<\/li>\n<li>RE104: Reunion Neuroscience (Postnatal depression)<\/li>\n<li>GM2505: Gilgamesh Pharmaceuticals (Major depressive disorder)<\/li>\n<li>EPX-100: Epygenix Therapeutics\/University of California at San Fransisco (Dravet syndrome; Lennox-Gastaut syndrome)<\/li>\n<li>BETR-001: BetterLife Pharma (Cluster headache; Major depressive disorder; Neuropathic pain; Post-traumatic stress disorders)<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Learn more about the emerging 5-HT2 agonist @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/5-ht2-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">5-HT2 Agonist Clinical Trials and FDA Approvals<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>5-HT2 Agonist Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>5-HT2 agonist pipeline<\/strong> report proffers an integral view of the emerging 5-HT2 agonist segmented by stage, product type, molecule type, and route of administration.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the 5-HT2 Agonist Pipeline Report <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>: Global<\/li>\n<li><strong>Therapeutic Assessment By Product Type: <\/strong>Mono, Combination, Mono\/Combination<\/li>\n<li><strong>Therapeutic Assessment By Clinical Stages: <\/strong>Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li><strong>Therapeutics Assessment<\/strong> <strong>By Route of Administration:<\/strong> Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal<\/li>\n<li><strong>Therapeutics Assessment<\/strong> <strong>By Molecule Type<\/strong>: Oligonucleotide, Peptide, Small molecule<\/li>\n<li><strong>Key 5-HT2 Agonist Companies<\/strong>: Cybin, Reunion Neuroscience, BetterLife Pharma, Gilgamesh Pharmaceuticals, Harmony Biosciences, Mindmed, ATAI LIFE SCIENCES N.V, Reviva Pharmaceuticals, Beckley Psytech, MindBio Therapeutics and others,<\/li>\n<li><strong>Key 5-HT2 Agonist Pipeline Therapies<\/strong>: CYB003, RE104, BETR-001, GM2505, EPX-100, MM120, EMP 01, Brilaroxazine, Psilocybin infusion, MB-22001 and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Dive deep into rich insights for new 5-HT2 agonists, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/5-ht2-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">5-HT2 Agonist Drugs and Medication<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. 5-HT2 Agonist Pipeline Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. 5-HT2 Agonist Pipeline Report Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. 5-HT2 Agonist Pipeline: Overview<\/p>\n<p style=\"text-align: justify;\">4. Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. 5-HT2 Agonist Clinical Trial Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. 5-HT2 Agonist Pipeline: Late-Stage Products (Pre-registration)<\/p>\n<p style=\"text-align: justify;\">7. 5-HT2 Agonist Pipeline: Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">8. 5-HT2 Agonist Pipeline: Mid-Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">9. 5-HT2 Agonist Pipeline: Early-Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">10. 5-HT2 Agonist Pipeline Therapeutics Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products in the 5-HT2 Agonist Pipeline<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Key Companies<\/p>\n<p style=\"text-align: justify;\">14. Key Products in the 5-HT2 Agonist Pipeline<\/p>\n<p style=\"text-align: justify;\">15. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=5ht2-agonist-clinical-trials-2025-ema-pdma-fda-approvals-medication-therapies-treatment-market-mechanism-of-action-route-of-administration-and-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=5ht2-agonist-clinical-trials-2025-ema-pdma-fda-approvals-medication-therapies-treatment-market-mechanism-of-action-route-of-administration-and-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>5-HT2 Agonist Clinical Trials 5-HT2 agonist companies such as Cybin, Reunion Neuroscience, BetterLife Pharma, Gilgamesh Pharmaceuticals, Harmony Biosciences, Mindmed, ATAI LIFE SCIENCES N.V, Reviva Pharmaceuticals, Beckley Psytech, MindBio Therapeutics and others. (Albany, USA) DelveInsight&rsquo;s &#8216;5-HT2 Agonist Pipeline Insight 2025&#8217; report &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/5ht2-agonist-clinical-trials-2025-ema-pdma-fda-approvals-medication-therapies-treatment-market-mechanism-of-action-route-of-administration-and-companies-by-delveinsight_752929.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-752929","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/752929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=752929"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/752929\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=752929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=752929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=752929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}